AR100762A1 - Sistema de liberación micelar a base del híbrido de peg-dendrón anfifílico que responde a enzimas - Google Patents

Sistema de liberación micelar a base del híbrido de peg-dendrón anfifílico que responde a enzimas

Info

Publication number
AR100762A1
AR100762A1 ARP150100556A ARP150100556A AR100762A1 AR 100762 A1 AR100762 A1 AR 100762A1 AR P150100556 A ARP150100556 A AR P150100556A AR P150100556 A ARP150100556 A AR P150100556A AR 100762 A1 AR100762 A1 AR 100762A1
Authority
AR
Argentina
Prior art keywords
agent
group
dendron
hybrid
release system
Prior art date
Application number
ARP150100556A
Other languages
English (en)
Inventor
Frid Liat
Rosenbaum Ido
Josef Harnoy Assaf
Buzhor Marina
Jacob Amir Roey
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of AR100762A1 publication Critical patent/AR100762A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un sistema de liberación híbrido anfifílico en forma micelar, que comprende un polímero de polietilenglicol hidrofílico (PEG) conjugado con un dendrón hidrofóbico, donde el dendrón comprende al menos un grupo terminal hidrofóbico enzimáticamente escindible que se une covalentemente con el dendrón, en donde la micela se desensambla después del clivaje enzimático del grupo terminal hidrofóbico. Reivindicación 34: El sistema de liberación hibrido de acuerdo con la reivindicación 32 ó 33, en donde el grupo terminal hidrofóbico que se une con el dendrón y/o el compuesto que está encapsulado por dicha micela están cada uno seleccionados, de modo independiente, del grupo que consiste en un agente antiproliferativo, un agente antiinflamatorio no esteroide, un agente antibiótico, un agente antimicrobiano, un agente antiviral, un agente inmunosupresor, un agente inmunomodulador, un agente antihipertensivo, un agente quimiosensibilizante, un agente antihistamínico, un agente anestésico general, un agente anestésico local, un agente analgésico, un agente antifúngico, una vitamina, una vitamina soluble en grasas, un agente hipnótico, un agente sedante, un agente ansiolítico, un agente antidepresivo, un agente anticonvulsivante, un agente analgésico narcótico, un agente antagonista narcótico, un agente anticolinesterasa, un agente simpatomimético, un agente parasimpatomimético, un agente estimulante gangliónico, un agente bloqueante gangliónico, un agente antimuscarínico, un agente bloqueante adrenérgico, un autacoide y antagonista de autacoide, digitalis y congéneres de digitalis, agentes diuréticos y saliuréticos, un agente reductor del colesterol, un agente antineoplásico, hemoglobina y derivados de hemoglobina y polímero, un agente hormonal, un agente antagonista hormonal y combinación de ellos. Reivindicación 35: El sistema de liberación híbrido de acuerdo con la reivindicación 34, en donde el grupo terminal hidrofóbico que se une con el dendrón y/o el compuesto que está encapsulado por dicha micela están cada uno seleccionados, de modo independiente, del grupo que consiste en cumarina, salicilato de metilo, aspirina, ibuprofeno, naproxeno, famciclovir, valaciclovir, aciclovir, penicilina-V, azlocilina, tetraciclina, daunorrubicina, doxorrubicina, antraciclina, mitomicina C, aminopertina, micofenolato mofetilo, azatioprina, sirolimus, glucocorticoide, metotrexato, azatioprina, ciclosporina, tacrolimus, talidomida, lenalidomida, pomalidomida, clorotiazida, metolazona, amiloride, acrivastina, bilastina, buclizina, cimetidina, clobenpropit, desflurano, isoflurano, sevoflurano, propofol, metohexital, benzocaina, dibucaina, lidocaína, proparacaína, paracetamol, morfina, oxicodona, celecoxib, flupirtina, anfotericina B, candicidina, bifonazol, butoconazol, fluconazol, abafungina, anidulafungina, retinol, tiamina, riboflavina, biotina, ergocalciferol, retinal, retinol, amobarbital, alprazolam, zopiclona, midazolam, amobarbital, alprazolam, sertralina, clobazam, codeina, naltrexona, fisostigmina, efedrina, dimetilfenilpiperazinio, pentamina, atropina, terazosina, histamina, hidroclorotiazida, estatina, tibolona, acetato de ganirelix, septrina y sus derivados. Reivindicación 36: El sistema de liberación hibrido de acuerdo con cualquiera de las reivindicaciones precedentes, está representado por la estructura de la fórmula (1), en donde R es H o un grupo alquileno C₁₋₄; T está ausente o es un grupo funcional seleccionado del grupo que consiste en -O-, -S-, -NH-, -C(=O)-, -O-C(=O)-O-, -C(=O)-O-, -C(=O)-NH-, -NH-C(=O)-NH-, NH-C(=O)-O-, -S(=O)-, -S(=O)-O-, PO(=O)-O-, -C=C-, -CºC-, -(CH₂)ₜ,- en donde t es un número entero de 1 - 10 y cualquiera de sus combinaciones; Y está ausente, de modo independiente en cada aparición, o es un resto de ligador / unidad de ramificación; Z es, de modo independiente en cada aparición, una unidad de repetición de dendrones seleccionada del grupo que consiste en: un resto seleccionado del grupo de fórmulas (2) y cualquier combinación de lo anterior; en donde X¹ está seleccionad, de modo independiente en cada aparición, del grupo que consiste en a O, S y NH; A es un grupo terminal hidrofóbico que se conjuga con el dendrón a través de un grupo funcional enzimáticamente escindible seleccionado del grupo que consiste en un éster, una amida, un carbamato, un carbonato, una urea, un sulfato, una amidina, un éter, un fosfato, una fosfoamida, sulfamatos, y un tritionato; n es un número entero en el rango de 1 a 1500, con preferencia, de 1 a 1000; y m y z son cada uno un número entero de 1 a 15.
ARP150100556A 2014-09-09 2015-02-25 Sistema de liberación micelar a base del híbrido de peg-dendrón anfifílico que responde a enzimas AR100762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462047697P 2014-09-09 2014-09-09

Publications (1)

Publication Number Publication Date
AR100762A1 true AR100762A1 (es) 2016-11-02

Family

ID=55458416

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100556A AR100762A1 (es) 2014-09-09 2015-02-25 Sistema de liberación micelar a base del híbrido de peg-dendrón anfifílico que responde a enzimas

Country Status (5)

Country Link
US (1) US20170348430A1 (es)
EP (1) EP3191137A4 (es)
CN (1) CN106687142A (es)
AR (1) AR100762A1 (es)
WO (1) WO2016038595A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100763A1 (es) * 2014-09-09 2016-11-02 Univ Ramot SISTEMA DE LIBERACIÓN DE AGROQUÍMICOS A BASE DE HÍBRIDOS DE PEG-DENDRÓN ANFIFÍLICO QUE RESPONDE A ENZIMAS O AL pH
US10869939B2 (en) 2015-08-03 2020-12-22 Ramot At Tel-Aviv University Ltd. Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers
CN109593158B (zh) * 2017-09-30 2021-02-26 浙江大学 一种γ-谷氨酰转肽酶催化水解致电荷翻转的聚合物及其在药物输送领域的应用
CN109998993A (zh) * 2019-04-22 2019-07-12 西南交通大学 用于治疗心血管类疾病的载药聚合物胶束及其制备方法和应用
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
AU2022293891A1 (en) * 2021-06-16 2024-01-04 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides for drug delivery applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080294089A1 (en) * 2007-06-06 2008-11-27 Biovaluation & Analysis, Inc. Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2011001657A1 (ja) * 2009-07-01 2011-01-06 独立行政法人科学技術振興機構 ポリイオンデンドリマー、及びそれよりなるハイドロゲル
US9457099B2 (en) * 2010-11-12 2016-10-04 Rutgers, The State University Of New Jersey Polyethylene glycol-based dendrons
EP2678042B1 (en) * 2011-02-23 2018-05-09 The Board of Trustees of the University of Illionis Amphiphilic dendron-coils, micelles thereof and uses
EP2707033A1 (en) * 2011-05-11 2014-03-19 Ramot at Tel Aviv University, Ltd. Targeted polymeric conjugates and uses thereof

Also Published As

Publication number Publication date
WO2016038595A1 (en) 2016-03-17
CN106687142A (zh) 2017-05-17
EP3191137A1 (en) 2017-07-19
EP3191137A4 (en) 2018-04-25
US20170348430A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
AR100762A1 (es) Sistema de liberación micelar a base del híbrido de peg-dendrón anfifílico que responde a enzimas
Caster et al. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
Xiao et al. Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance
Arzani et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge
Liu et al. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery
Lu et al. Targeted delivery of doxorubicin by folic acid-decorated dual functional nanocarrier
Lu et al. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance
Sun et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance
Jin et al. Soluplus® micelles as a potential drug delivery system for reversal of resistant tumor
Denora et al. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain
Li et al. On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier
Xie et al. Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy
Oberoi et al. PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination
Liu et al. Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier
WO2010039496A3 (en) Nanocarriers for drug delivery
Garg et al. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles
US20110195030A1 (en) Nanoparticle compositions comprising liquid oil cores
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
Zhang et al. Nanomicellar carriers for targeted delivery of anticancer agents
NO20083573L (no) Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler
UA113549C2 (xx) Біорозкладений засіб доставки лікарських засобів для гідрофобних композицій
Famta et al. Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms
Tian et al. Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells
Jabri et al. Design and synthesis of mixed micellar system for enhanced anticancer efficacy of Paclitaxel through its co-delivery with Naringin
WO2006113505A3 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Legal Events

Date Code Title Description
FB Suspension of granting procedure